COVID-19 mortality reduced 4X (chart looks like 2X) by large, infrequent doses of Vitamin D in France

Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: Extension phase of the GERIA-COVID study

J Steroid Biochem Mol Biol. 2021 Jul 28;105958. doi: 10.1016/j.jsbmb.2021.105958

Cédric Annweiler 1, Mélinda Beaudenon 2, Romain Simon 2, Mialy Guenet 2, Marie Otekpo 2, Thomas Célarier 3, Jennifer Gautier 2, GERIA-COVID study group

image

Note: This study combined all infrequent dosing into intervention data * 50,000IU per month, or * 80,000IU or 100,000IU or 200,000IU every 2-3 months Note: The vitamin D levels did not rise very much for those getting this small amount of vitamin D Note: 2-3 months dosing produces less than half the response as monthly dosing 1. # Items in both categories Virus and Loading Dose are listed here: {category} --- Loading Dose of Vitamin D category has the following {include} Note: >70% of the RCT using Vitamin D to fight COVID-19 are using at least 100,000 IU during the first week image

Download the PDF from VitaminDWiki

image

VitaminDWiki suspect that there is data error.
The above table shows that those supplementing had LOWER vitamin D levels

Background: The objective of this extension phase of the quasi-experimental GERIA-COVID study was to determine whether vitamin D3 supplementation taken prior to or during COVID-19 was associated with better 3-month survival in geriatric patients hospitalized for COVID-19.

Methods: Intervention group was defined as all participants supplemented with vitamin D3 prior to or during COVID-19 (n = 67). Supplements were either bolus vitamin D3 (ie, 50,000IU per month, or 80,000IU or 100,000IU or 200,000IU every 2-3 months), or daily supplementation with 800IU. Comparator group involved those without vitamin D supplements (n = 28). Outcome was 3-month mortality. Covariables were age, sex, functional abilities, history of malignancies, cardiomyopathy, undernutrition, number of acute health issues, antibiotics use, systemic corticosteroids use, and 25(OH)D concentration.

Results: 76.1% (n = 51) of participants survived at 3 months in Intervention group, compared to only 53.6% (n = 15) in Comparator group (P = 0.03). The fully-adjusted hazard ratio for 3-month mortality was HR = 0.2395%CI:0.09;0.58 in Intervention group compared to Comparator group. Intervention group had also longer survival time (log-rank P = 0.008).

Conclusions: Vitamin D3 supplementation was associated with better 3-month survival in older COVID-19 patients.